Ru eye plaques contain data for only 1 single eye plaque. For this reason, differences in dose distributions between different publications cannot be easily attributed to methodical differences on the one hand or differences in the heterogeneous distribution of the emitter substance of the eye plaques themselves on the other. Furthermore, this inhomogeneity is one of the reasons why Monte Carlo-simulated depth dose curves [2] differ from measured ones especially regarding absolute doses ( Fig. 2 ) . The manufacturer BEThis letter is a supplement to the paper of Zaragoza et al. [1] . In this publication, the impact of the heterogeneous distribution of the emitter substance of 106 Ru eye plaques on the dose distribution and the treatment planning are exemplarily shown for 2 eye plaques of the CCB and CCA types. The investigated CCB-type eye plaque (serial number 1256) shows inhomogeneities in dose distributions of about 25% with respect to the ideal homogenous plaque. As a 22 BIG delivers a certificate for every individual eye plaque in which a depth-dose curve and a surface-dose distribution consisting of 33 measuring points are documented. The differences in the heterogeneous distribution of the emitter substance are reflected in the depth dose and by this are sufficiently considered for treatment planning. Alternatively, the 33 measuring points can be entered in the Plaque simulator, a treatment planning software (Eye Physics LLC, Los Alamitos, CA, USA), to estimate the dose distribution of the eye plaque. Caused by only a few measuring points, the variation in surface dose distributions is only illustrated to some degree, and their impact on side effects cannot be fully considered. Thus, at the Technical University of Dortmund, a high-precision dosimetry system was developed, which allows for complete measurements of surface-dose distributions of eye plaques [3, 4] . One of these data sets is the basis for the Monte Carlo simulations of inhomogeneous plaques recently shown by Zaragoza et al. [1] . Note the large variation of surface-dose distributions measured close to the plaque surface for 5 randomly chosen CCB-type plaques ( Fig. 1 ) . As already said by Zaragoza et al. [1] , 106 Ru eye plaques are very effective for tumors with a tumor thickness of up to 4 mm, and the impact of the inhomogeneous distribution of the 106 Ru eye plaques is negligible. In the case of tumors with tumor thicknesses up to 6 mm, the influence of the inhomogeneous distribution becomes larger. A safe treatment needs a detailed knowledge of the dose distribution of the used eye plaque type to assure complete dose coverage of the entire tumor mass plus a sufficient safety margin and to avoid surpassing the dose tolerated by the sclera. [2] and different eye plaques of the CCB type. Data are taken from BEBIG certificates for sealed radioactive sources.
